Pharmaceuticals India News
  • Home
  • Brands
    • Alkem
    • Apollo Hospital
    • Aurobindo Pharma
    • Biocon
    • Cipla
    • Divi’s Laboratories
    • Dr Reddy’s
    • Fortis
    • Glenmark
    • Lupin
    • Mankind Pharma
    • Natco
    • Pfizer
    • Piramal Pharma
    • Sun Pharma
    • Torrent Pharma
    • Zydus
Select Page

Sekhmet Pharma, owned by private equity, appoints ex-Lupin and Shilpa Medicare executive as its new chief executive officer.

by Team Small News | Jun 4, 2025 | Lupin, Pharma

A private equity consortium led by PAG, an Asia-focused investment firm, has announced the appointment of Santosh Kumar Mahil as the Managing Director and CEO of Sekhmet Pharmaventures Pvt Ltd. Mahil replaces Anil Khubchandani, who was appointed to the role in 2023....

Major pharmaceutical companies, including AstraZeneca, Pfizer, and Gilead, have made public their findings on new cancer treatments.

by Team Small News | Jun 4, 2025 | Pfizer, Pharma

The American Society of Clinical Oncology (ASCO) annual meeting was held in Chicago, featuring over 5,000 research abstracts on various cancer treatments and studies. Several pharmaceutical giants and biotech companies presented promising data, including AstraZeneca,...
Delhi High Court bars Dr. Reddy’s and OneSource from selling weight loss medication in India due to patent infringement concerns.

Delhi High Court bars Dr. Reddy’s and OneSource from selling weight loss medication in India due to patent infringement concerns.

by Team Small News | Jun 2, 2025 | Dr Reddy's

The Delhi High Court has issued an ad interim injunction to restrain Dr. Reddy’s Laboratories and its distributor, OneSource Pharma, from selling a weight loss drug in India. This decision comes amid a patent dispute with Glenmark Pharmaceuticals, which claims...

Nomura elevates price target for Fortis Healthcare, retains ‘buy’ rating, reports Medical Buyer

by Team Small News | Jun 2, 2025 | Fortis, Pharma

Nomura, a research firm, has revised its price target for Fortis Healthcare from Rs 700 to Rs 820, while maintaining its “buy” rating. The firm attributes this increase to the company’s strong growth prospects, driven by its existing infrastructure...

Glenmark Pharmaceuticals’ (NSE:GLENMARK) financial results appear less impressive upon closer examination.

by Team Small News | Jun 2, 2025 | Glenmark, Pharma

Glenmark Pharmaceuticals’ latest earnings report may appear impressive at first glance, but a closer examination reveals some underlying weaknesses. The company’s net profit increased by 15.6% year-over-year, reaching ₹2.16 billion, and revenue grew by...
« Older Entries
Next Entries »

_________

Pharna Brands

  • Alkem
  • Apollo Hospital
  • Aurobindo Pharma
  • Biocon
  • Cipla
  • Divi’s Laboratories
  • Dr Reddy’s
  • Fortis
  • Glenmark
  • Lupin
  • Mankind Pharma
  • Natco
  • Pfizer
  • Piramal Pharma
  • Sun Pharma
  • Torrent Pharma
  • Zydus
  • Alkem
  • Apollo Hospital
  • Aurobindo Pharma
  • Biocon
  • Cipla
  • Torrent Pharma
  • Divi’s Laboratories
  • Dr Reddy’s
  • Fortis
  • Glenmark
  • Lupin
  • Zydus
  • Mankind Pharma
  • Natco
  • Pfizer
  • Piramal Pharma
  • Sun Pharma

    Designed by Elegant Themes | Powered by WordPress